SPY311.36-0.82 -0.26%
DIA263.33+0.16 0.06%
IXIC9,615.81-67.10 -0.69%
News
ADMP
--
0.00%
--
Adamis Pharmaceuticals Announces Publication of Pharmacokinetic study comparing ZIMHI to current 2 mg intramuscular dose of naloxone
GlobeNewswire · 05/27 14:00
Adamis Pharma Highlights Publication Of Pharmacokinetic Study Comparing ZIMHI To Current 2 mg Intramuscular Dose Of Naloxone
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) announced today the publication of an article entitled “An open-label, randomized, single-dose, two-period, two-treatment crossover
Benzinga · 05/27 13:02
Adamis Pharmaceuticals: Barely Holding On After Q1 Report
Seeking Alpha - Article · 05/27 00:55
Edited Transcript of ADMP earnings conference call or presentation 18-May-20 9:00pm GMT
Thomson Reuters StreetEvents · 05/25 15:37
The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces $1.34B Common Stock Offering
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 18)
Benzinga · 05/19 12:27
Adamis Pharmaceuticals Corporation (ADMP) CEO Dennis Carlo on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/19 02:00
Adamis Pharmaceuticals EPS misses by $0.08, misses on revenue
Adamis Pharmaceuticals (NASDAQ:ADMP): Q1 GAAP EPS of -$0.15 misses by $0.08. Revenue of $4.66M (-5.1% Y/Y) misses by $0.92M. Shares +1.4%. 10Q Press Releas
seekingalpha · 05/19 01:38
Adamis Pharmaceuticals Announces First Quarter 2020 Financial Results and Business Update
GlobeNewswire · 05/18 21:35
Adamis Pharmaceuticals Q1 EPS $(0.110) Misses $(0.040) Estimate, Sales $4.663M Miss $6.870M Estimate
Adamis Pharmaceuticals (NASDAQ:ADMP) reported quarterly losses of $(0.110) per share which missed the analyst consensus estimate of $(0.040) by 175 percent. This is a 42.11 percent increase over losses of $(0.190) per
Benzinga · 05/18 20:39
Adamis Pharmaceuticals Resubmits ZIMHI New Drug Application to FDA
GlobeNewswire · 05/18 14:00
The Week Ahead In Biotech: Aquestive Awaits FDA Decision, Earnings Flow Slows
Biotech stocks had another up week, with the American Society of Gene & Stem Cell Therapy virtual conference presentations and the ASCO abstracts made available online Thursday calling the shots. Earnings news flow continued to taper.
Benzinga · 05/17 16:30
Adamis Pharmaceuticals Schedules First Quarter 2020 Earnings Conference Call and Business Update
GlobeNewswire · 05/15 14:00
Maxim Group Upgrades Adamis Pharmaceuticals to Buy, Announces $1.5 Price Target
Maxim Group analyst Jason McCarthy upgrades Adamis Pharmaceuticals (NASDAQ:ADMP) from Hold to Buy and announces $1.5 price target.
Benzinga · 05/13 15:34
Adamis Pharma +8% on Symjepi and Zimhi deal
Seeking Alpha - Article · 05/12 11:13
Adamis Pharmaceuticals Provides Update on SYMJEPI Products and Announces Distribution and Commercialization Agreement for SYMJEPI and ZIMHI Products
GlobeNewswire · 05/12 01:35
Adamis (ADMP) Moves to Strong Buy: Rationale Behind the Upgrade
Zacks · 04/29 17:00
Adamis Pharmaceuticals Announces Publication Demonstrating PET Scan Results of Higher Dose Naloxone in Monkeys
GlobeNewswire · 04/23 14:00
Adamis Pharma Highlights Publication Of 'The Effects of Intramuscular Naloxone Dose on Mu Receptor Displacement of Carfentanil in Rhesus Monkeys' In 'Molecules'
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) announced publication in the peer reviewed journal Molecules, “The Effects of Intramuscular Naloxone Dose on Mu Receptor Displacement of
Benzinga · 04/23 13:06
Adamis Pharmaceuticals: Trying To Find A Course Of Action
Seeking Alpha - Article · 04/16 22:25
Adamis Pharmaceuticals Announces Receipt of Loan Proceeds Under Paycheck Protection Program
GlobeNewswire · 04/15 21:05